XML 14 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Jun. 30, 2024
Sep. 30, 2023
Current Assets:    
Cash and cash equivalents $ 17,911,192 $ 26,480,928
Prepaid expenses 10,094,597 7,889,506
Total Current Assets 28,005,789 34,370,434
Property and equipment, net 1,432
Operating lease right-of-use asset, net 299,932 454,426
Deposits 38,062 38,062
In-process research and development 59,400,000 59,400,000
Goodwill 9,346,796 9,346,796
Total Assets 97,090,579 103,611,150
Current Liabilities:    
Accounts payable 1,663,336 2,927,334
Accrued expenses 550,485 476,300
Accrued compensation 1,702,668 2,156,983
Operating lease liability 235,581 218,380
Total Current Liabilities 4,152,070 5,778,997
Deferred tax liability 6,569,800 6,137,800
Operating lease liability – noncurrent 84,430 262,865
Total Liabilities 10,806,300 12,179,662
Commitments and Contingencies
Stockholders’ Equity:    
Preferred stock – $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock – $0.001 par value; 400,000,000 shares authorized; 180,725,407 and 158,857,798 shares issued and outstanding at June 30, 2024 and September 30, 2023, respectively 180,725 158,858
Additional paid-in capital 276,083,228 252,903,629
Accumulated deficit (190,580,054) (162,231,379)
Total Citius Pharmaceuticals, Inc. Stockholders’ Equity 85,683,899 90,831,108
Non-controlling interest 600,380 600,380
Total Equity 86,284,279 91,431,488
Total Liabilities and Equity $ 97,090,579 $ 103,611,150